Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA. METHODS: Data were pool...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Rheum Dis
Main Authors: Cohen, Stanley B, Tanaka, Yoshiya, Mariette, Xavier, Curtis, Jeffrey R, Lee, Eun Bong, Nash, Peter, Winthrop, Kevin L, Charles-Schoeman, Christina, Thirunavukkarasu, Krishan, DeMasi, Ryan, Geier, Jamie, Kwok, Kenneth, Wang, Lisy, Riese, Richard, Wollenhaupt, Jürgen
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Clinical and Epidemiological Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5530353/
https://ncbi.nlm.nih.gov/pubmed/28143815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2016-210457
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados